News | Nuclear Imaging | May 09, 2022

This action has been taken out of an abundance of caution as a result of potential quality issues identified in its manufacturing processes

This action has been taken out of an abundance of caution as a result of potential quality issues identified in its manufacturing processes

May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey. The company has taken this action out of an abundance of caution as it addresses potential quality issues identified in its manufacturing processes. Novartis is conducting a thorough review of the situation and currently expects to resolve the issues and resume some supply in the next six weeks.

As a result, the company is temporarily suspending delivery of Lutathera (USAN: lutetium Lu 177 dotatate; INN: lutetium (177Lu) oxodotreotide) in the US and Canada, and 177Lu-PSMA-617 (INN: lutetium (177Lu) vipivotide tetraxetan), marketed as Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in the US. Some doses of Lutathera (lutetium (177Lu) oxodotreotide) will be available in Europe and Asia from Novartis radioligand therapy production site in Zaragoza, Spain, although there may be some delays in supply.

In addition, Novartis is putting a temporary hold on screening and enrollment for 177Lu-PSMA-617 clinical trials globally, and Lutathera clinical trials in the US and Canada.

Quality and patient safety are our top priorities. There is currently no indication of any risk to patients from doses previously produced at these sites. Novartis has notified treatment sites to closely monitor patients who have recently been injected and asked them to report any adverse events to Novartis patient safety.

In a published statement, the company said it recognizes that this situation affects patients, their families and care teams. Novartis takes this very seriously and the company is doing everything it can to resolve this issue and resume patient doses as quickly as possible. Health authorities have been informed and will receive additional updates as they are available.

For more information: www.novartis.com

Related Medical Radioisotopes Content:

University of Missouri Research Reactor Helps Supply Critical Medical Isotopes During Global Disruption

Update on Unplanned Outage of the HFR Reactor

SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals

How Nuclear Fusion is Revolutionizing Medical Isotope Production

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes

Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m

VIDEO: Advances in Radiopharmaceutical Therapy


Related Content

News | PET Imaging

March 23, 2023 — Nuclidium announced that the Neuroendocrine Tumors Research Foundation (NETRF) has selected the company ...

Time March 24, 2023
arrow
News | Nuclear Imaging

March 22, 2023 — A novel imaging modality that can visualize the distribution of medical radiopharmaceuticals with very ...

Time March 22, 2023
arrow
News | PET-CT

March 21, 2023 — Positron Corporation, a molecular imaging device company that offers PET imaging systems and clinical ...

Time March 21, 2023
arrow
News | Radiopharmaceuticals and Tracers

March 20, 2023 — RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against ...

Time March 20, 2023
arrow
News | Radiopharmaceuticals and Tracers

March 16, 2023 — A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to ...

Time March 16, 2023
arrow
News | Contrast Media

March 9, 2023 — Contrast agents used in MRI scans to improve the clarity of imaging for diagnostic accuracy, accumulate ...

Time March 09, 2023
arrow
News | Contrast Media

March 2, 2023 — GE HealthCare announced at the European Congress of Radiology (ECR) in Vienna, Austria, the completion ...

Time March 02, 2023
arrow
News | PET Imaging

February 23, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of ...

Time February 23, 2023
arrow
News | Contrast Media

February 16, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

Time February 16, 2023
arrow
Subscribe Now